Daily News Digest

by Mark Zalewski

July 7, 2016

In today’s CT Daily News Digest: Van Avermaet does the double! BMC rider takes Tour de France stage win, yellow jersey; Giro Rosa Round-up: Wiggle-High5 continues Italian success with stage win and pink for Mara Abbott; Jan Hirt wins Austria queen stage, takes over lead; Andrei Nechita wins Sibiu Cycling Tour prologue; Operación Puerto samples in UCI, WADA custody; WADA extends Meldonium grace period through September; The return of Marcel Kittel: ‘I know how hard the way back to this moment was’; Trans Am reflections: Race lead, blue feet, altitude sickness and a gender paradigm shift; Bahrain team on hold until 2018?; Sunweb possibly joining Giant as new title sponsor; Oleg Tinkoff: “If Sagan wins two stages, I stay in cycling”; Tour de France, stage 4 on-board highlights; Celebrating Kittel’s stage win; Peter Sagan: “Life is like a movie”; What does it take to ride in a breakaway at Le Tour?

WADA extends Meldonium grace period through September

by CyclingTips

The addition of meldonium to the prohibited substance list by the World Anti-doping Association (WADA), effective 1 January of this year, caught many athletes off-guard and resulted in 172 athletes testing positive. Many of the athletes were Russian, including tennis superstar Maria Sharapova and professional cyclist Eduard Vorganov (Katusha). WADA has since clarified its position and has established a grace period for athletes who claim to have taken meldonium before 2016 until 30 September.


After the initial positives the Russian Sports Ministry quickly argued that the science determining how long meldonium remains in the body after ingestion was inconclusive and that athletes could have taken the drug before 1 January but stopped after the ban began and still tested positive.

In response WADA agreed, stating in a memo in April that, “There is currently a lack of clear scientific information on excretion times.” WADA subsequently commissioned scientific studies to better determine the timetables.

Based on the early results of some of the studies, WADA last week established guidance around meldonium, with a grace period through 30 September of this year. The specific amounts allowable are determined by collection date of the sample.

“We are pleased that the necessary urinary excretion studies have now progressed, and that the guidance we are now able to provide our stakeholders to help them manage meldonium cases is clear and scientifically robust,” WADA President Craig Reedie said.

Click through to read more at WADA.